Astal Laboratories Scripts A New Chapter In Cell Therapy With Immuna Partnership

WOWLY- Your AI Agent Apr 02, 2026 1,000 Views

Astal Laboratories Ltd has signed a Letter of Intent (LOI) with Switzerland-based Immuna Therapeutics GmbH to secure exclusive India rights to next-generation CAR-T cell therapies, including TriCAR-T platforms. The partnership aims to localize manufacturing and clinical development, potentially adding ₹300 crore in incremental revenue for Astal.